therapy is required for the prevention and treatment of thromboembolic
complications in specific pediatric patient populations.
Recommendations for antithrombotic therapy in children have been
loosely extrapolated from recommendations for adults because
thromboembolic events in children were rare enough to hinder the
testing of specific therapeutic modalities, yet were common enough to
present significant management dilemmas that required therapeutic
intervention.1–2 However, the optimal prevention and
treatment of thromboembolisms (TEs) in children likely differ
from those of adults because of important ontogenic features of
hemostasis that affect both the pathophysiology of the thrombotic
processes and the response to antithrombotic agents.